Biopharmaceutics: Dose Adjustment in Renal Impairment
1. Introduction: Pharmacokinetic Changes in Renal Impairment
Renal impairment significantly alters the pharmacokinetics of drugs, necessitating dose adjustments to avoid toxicity while maintaining therapeutic efficacy. The key pharmacokinetic parameters affected are: Volume of Distribution (VD), Clearance (Cl), and Elimination Half-life (t1/2).
Note: Uremia refers to the clinical condition associated with kidney failure, where waste products accumulate in the blood.
2. Effects on Volume of Distribution (VD)
Renal impairment may alter drug distribution due to:
- Changes in fluid balance
- Alterations in drug-protein binding
- Other physiological factors
2.1 Drug-Protein Binding in Uremia
- The plasma protein binding of weak acidic drugs in uremic patients is decreased.
- The protein binding of weak basic drugs is less affected.
Consequence: Decreased drug-protein binding → Larger fraction of free drug → Increase in the volume of distribution.
3. Effects on Clearance (Cl)
The total body clearance (ClT) of drugs in uremic patients is reduced due to:
- Decrease in glomerular filtration rate (GFR)
- Possible reduction in active tubular secretion
- Reduced hepatic clearance (for some drugs)
4. General Approaches for Dose Adjustment in Renal Disease
There are two general pharmacokinetic approaches for dose adjustment in renal disease:
4.1 Approaches Based on Drug Clearance
According to this method, the total body clearance (ClT) changes. The calculation for average steady-state concentration (Cav) is based on multiple dosing:
Cav = (F × D0) / (ClT × τ)
Where:
F = Fraction of drug absorbed
D0 = Dose of the drug
τ = Dosing interval
4.2 Approaches Based on Elimination Half-life or Elimination Rate Constant
This method utilizes the relationship between renal function and drug elimination kinetics to adjust dosing regimens.
5. Measurement of Renal Function
5.1 Glomerular Filtration Rate (GFR)
GFR is a key indicator of renal function and can be measured using various methods.
Clinical Insight: In practice, GFR obtained from a patient may sometimes be higher than expected due to methodological variations or specific physiological conditions.
5.2 Creatinine Clearance (Clcr)
Creatinine clearance is defined as the rate of urinary excretion of creatinine relative to its serum concentration.
Clcr = (Rate of urinary excretion of creatinine) / (Serum concentration of creatinine)
Creatinine clearance is clinically expressed in mL/min, with serum creatinine concentration typically in mg/dL.
Clcr = (CU × V × 100) / (Ccr × 1440)
Where:
CU = Urinary creatinine concentration (mg/mL)
V = Urine volume (mL)
Ccr = Serum creatinine concentration (mg/dL)
1440 = Minutes in a day (for 24-hour urine collection)
6. Direct Methods to Estimate Creatinine Clearance from Plasma Creatinine
Several methods are available for estimating creatinine clearance without 24-hour urine collection. The more accurate methods incorporate patient age, height, weight, and gender.
6.1 For Adults
A. The Jelliffe Method (1973)
Applicable for adult patients aged 20-80 years. This method recognizes that older patients have lower creatinine clearance for the same serum creatinine concentration.
For males: Clcr = 98 - 0.8 × (Age - 20)
For females: Clcr = [98 - 0.8 × (Age - 20)] × 90%
B. The Cockcroft & Gault Method
This widely used method incorporates both age and body weight.
For males: Clcr = [(140 - Age) × Body weight (kg)] / (72 × Serum creatinine)
For females: Clcr = [(140 - Age) × Body weight (kg) × 0.85] / (72 × Serum creatinine)
C. Nomogram Method
A graphical method that estimates creatinine clearance based on age, weight, and serum creatinine concentration.
Nomogram Procedure:
- Connect the patient's weight (line 2) with the patient's age (line 4) using a ruler.
- Note the intersection point on reference line R.
- Align the right point of the ruler with the serum creatinine value; the left side will indicate the clearance in mL/min.
6.2 For Children
A. Schwartz Method
For calculation of creatinine clearance in children based on body length and serum creatinine:
ClCr = (0.55 × Body length in cm) / Serum creatinine
Where ClCr is given in mL/min/1.73 m²
7. Practical Examples and Calculations
Example 1: Basic Creatinine Clearance Calculation
Given: CU = 0.1 mg/mL, V = 1.8 L (1800 mL), Ccr = 2.2 mg/dL
Clcr = (CU × V × 100) / (Ccr × 1440)
Clcr = (0.1 × 1800 × 100) / (2.2 × 1440)
Clcr = 18000 / 3168
Clcr = 5.69 mL/min ≈ 5.7 mL/min
Interpretation: The uremic dose should be approximately 5.7% of the normal dose for a drug that is primarily renally eliminated.
If normal dose = 20 mg/day, then uremic dose = (5.7/100) × 20 = 1.14 mg/day
Dosing frequency adjustment might be needed (e.g., every 6 hours for drugs with short half-lives).
Example 2: Gentamicin Dose Adjustment
Scenario: The usual dose of gentamicin in a patient with normal renal function is 10 mg every 8 hours by multiple IV bolus injection. What dose would be recommended for a 55-year-old adult male patient weighing 72 kg with a creatinine clearance of 20 mL/min?
Given: Gentamicin is 100% excreted by the kidney.
KU/KN = 0.2 (20% of normal renal function)
Uremic dose (DU) = 20% of normal dose
If normal dose = 1 mg/kg (assumed from context), then:
DU = (20/100) × 1 mg/kg = 0.20 mg/kg
For a 72 kg patient: DU = 0.20 × 72 = 14.4 mg
Recommendation: The patient should receive 14.4 mg every 8 hours by multiple IV bolus injection.
8. Important Considerations in Clinical Practice
Key Points:
- Dose adjustment is critical for drugs with a narrow therapeutic index that are primarily renally excreted.
- Always consider both loading and maintenance dose adjustments.
- Monitor drug levels whenever possible, especially for drugs like aminoglycosides, vancomycin, and digoxin.
- Consider non-renal clearance pathways that might also be affected in renal impairment.
- Account for changes in protein binding that might alter free drug concentrations.
Clinical Caution: These calculations provide estimates. Individual patient factors (comorbidities, concomitant medications, fluid status) must be considered. Always consult current clinical guidelines and practice standards.
